These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8785997)

  • 1. Reducing the use of the target animal batch safety test for veterinary vaccines.
    Roberts B; Lucken RN
    Dev Biol Stand; 1996; 86():97-102. PubMed ID: 8785997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs.
    De Mattia F; Chapsal JM; Descamps J; Halder M; Jarrett N; Kross I; Mortiaux F; Ponsar C; Redhead K; McKelvie J; Hendriksen C
    Biologicals; 2011 Jan; 39(1):59-65. PubMed ID: 21277791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency as tool to support in vitro batch potency testing in GMP production.
    Stirling C
    Dev Biol (Basel); 2012; 134():115-8. PubMed ID: 22888603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement, reduction or refinement of animal use in the quality control of veterinary vaccines: development, validation and implementation.
    van der Kamp MD
    Dev Biol Stand; 1996; 86():73-6. PubMed ID: 8785994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reduction of the use of challenge testing to provide evidence of efficacy in tests of immunological veterinary medicinal products (IVMPs).
    Webster CJ
    Dev Biol Stand; 1996; 86():103-9. PubMed ID: 8785938
    [No Abstract]   [Full Text] [Related]  

  • 9. Control of product batches (before and after registration). The German approach.
    Jungbäck C
    Dev Biol Stand; 1992; 79():171-4. PubMed ID: 1286753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The validation of potency tests: hurdles identified by EMA/CVMP/IWP.
    Woodland R
    Dev Biol (Basel); 2012; 134():69-73. PubMed ID: 22888597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vaccines consistency approach project: an EPAA initiative.
    De Mattia F; Hendriksen C; Buchheit KH; Chapsal JM; Halder M; Lambrigts D; Redhead K; Rommel E; Scharton-Kersten T; Sesardic T; Viviani L; Ragan I
    Pharmeur Bio Sci Notes; 2015; 2015():30-56. PubMed ID: 26830158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential application of the consistency approach for vaccine potency testing.
    Arciniega J; Sirota LA
    Dev Biol (Basel); 2012; 134():135-9. PubMed ID: 22888606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The five Rs: refinement, reduction, replacement. A regulatory revolution.
    Lucken RN
    Dev Biol Stand; 1996; 86():67-72. PubMed ID: 8785993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three Rs Approaches in the Production and Quality Control of Fish Vaccines.
    Midtlyng PJ; Hendriksen C; Balks E; Bruckner L; Elsken L; Evensen O; Fyrand K; Guy A; Halder M; Hawkins P; Kisen G; Romstad AB; Salonius K; Smith P; Sneddon LU
    Biologicals; 2011 Mar; 39(2):117-28. PubMed ID: 21371907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global harmonization of vaccine testing requirements: Making elimination of the ATT and TABST a concrete global achievement.
    Viviani L; Halder M; Gruber M; Bruckner L; Cussler K; Sanyal G; Srinivas G; Goel S; Kaashoek M; Litthauer D; Lopes da Silva AL; Sakanyan E; Aprea P; Jin H; Vandeputte J; Seidle T; Yakunin D
    Biologicals; 2020 Jan; 63():101-105. PubMed ID: 31699501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reduction of animal experiments in experimental drug testing].
    Behrensdorf-Nicol H; Krämer B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1173-80. PubMed ID: 25183445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The target animal safety test--is it still relevant?
    Advisory Group on Alternatives to Animal Testing in Immunobiologicals
    Biologicals; 2002 Dec; 30(4):277-87. PubMed ID: 12474863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of product batches (before and after registration). The Belgian approach.
    Pensaert M
    Dev Biol Stand; 1992; 79():183-6. PubMed ID: 1286756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
    Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
    ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the relevance of the target animal safety test for the quality control of veterinary immunological medicinal products.
    Pöbetanecker A; Cubetaler K
    ALTEX; 1998; 15(5):71-75. PubMed ID: 11178548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.